Mana.bio Overview
Mana.bio specializes in AI-based drug-delivery solutions, with a focus on gene therapy. The companys technology integrates machine learning and nanotechnology for the development of drug-delivery systems. Mana.bio has created a platform for lipid nanoparticle development for oligonucleotide therapies, including mRNA-based therapeutics, vaccines, and gene therapy. The technology is powered by an integration of machine learning and nanotechnology in order to identify formulations of lipid nanoparticles drug delivery systems.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- Mana.bio, a biotechnology company pioneering the intersection of artificial intelligence and RNA delivery, today announced the launch of Mina™,...
Mana.bio, a biotechnology company, has launched Mina™, the first large language model specifically designed for lipid nanoparticles (LNPs). This AI-powered tool, described as a ChatGPT for LNPs, is publicly available for free and aims to accelerate scientific discovery in RNA delivery and therapeutics development. Mina provides predictive modeling, curated data retrieval, and formulation optimization to enhance research and innovation in gene therapy and RNA-based medicines. The launch of Mina represents a significant advancement in AI-driven platforms for scientific research, bridging the gap between laboratory research and clinical application. Mana.bio is committed to collaborating with partners to leverage Minas capabilities.
Product Stage
growth-positive
/PRNewswire/ -- Mana.bio, a seed-stage biotech company pioneering the use of artificial intelligence (AI) and machine learning (ML) to design lipid...
Mana.bio, a seed-stage biotech company, is pioneering the use of AI and ML to design lipid nanoparticles (LNP) for RNA therapeutics. At the 3rd annual LNP Immunogenicity & Toxicity Summit in Boston on December 10, 2024, Mana.bio presented data demonstrating significant advancements in their AI-driven LNP delivery platform. Their second-generation LNP candidate showed a 100-fold increase in in-vivo potency after three months of iterative development. The company is leveraging AI to expedite drug development, potentially reducing timelines by years. Mana.bios platform integrates public and proprietary data to train ML models, optimizing LNP for potency and safety. The company plans to attend the JP Morgan Healthcare conference in January 2024.
Biotech startup Mana.bio raises $19.5 million Seed to accelerate programmable drug delivery | CTech
growth-positive
Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver
Mana.bio, a new startup based in Tel Aviv, Israel, has raised $19.5 million in seed financing. The company aims to address one of the biggest challenges facing genetic medicines - delivering them to the right part of the body. The funding round was led by Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, and Technion — Israel Institute of Technology.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $24.5M |
| Last funding | $19.5M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 5 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | www.mana.bio/ |
| Careers | Careers page |
Locations
Haifa, Israel
Tel Aviv, Israel
Photos & Videos
No files yet
